Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer

Li Li, Limei Wang, Wei Zhang, Bujian Tang, Jieqing Zhang, Honglin Song, Desheng Yao, Yong Tang, Xinqiu Chen, Zhihua Yang, Gangduo Wang, Xiping Li, Jinshun Zhao, Hong Ding, Eddie Reed, Qingdi Q. Li

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF) has been shown to play an important role in tumor growth and progression. However, the clinical implications of VEGF expression in ovarian tumors are not fully understood. We therefore investigated the serum level of VEGF in patients with ovarian tumors and explored the potential use of VEGF as a tumor marker for diagnosis, treatment and prognosis of human ovarian cancer. The serum VEGF (sVEGF) levels in 120 patients with ovarian carcinoma, 25 patients with benign ovarian tumor and 90 healthy female blood donors were measured by an enzyme-linked immunosorbent assay in this study. We also determined the levels of sVEGF in patients with epithelial ovarian cancer before and after surgery. Our results showed that: (i) ovarian cancer patients had significantly higher levels of sVEGF compared to those of patients with benign ovarian tumor or those of healthy individuals. As a cut-off at 100 pg/ml, the sensitivity and specificity of sVEGF levels for diagnosing ovarian carcinoma were 77.1% and 87%, respectively. (ii) sVEGF levels were markedly elevated in patients with advanced stage or poorly-differentiated ovarian cancer, as well as in those with more ascites (>500 ml), as compared to patients with early stage and well-differentiated ovarian cancer, or those with less ascites (<500 ml). However, there was no significant difference in sVEGF levels among different pathological subtypes of ovarian carcinoma. (iii) The postoperative sVEGF levels were significantly lower than the preoperative sVEGF levels. (iv) We measured significantly higher levels of sVEGF in patients with metastasis as compared to patients lacking metastasis. Lastly, (v) the average survival-time in patients with higher levels of sVEGF (>100 pg/ml) was 28 months, while the average survival-time in patients with lower levels of sVEGF (<100 pg/ml) was 35 months, indicating that the elevations in sVEGF level are correlated with patient survival and tumor metastasis in ovarian carcinoma. These data suggest that VEGF may be a useful serological biomarker for clinical diagnosis and prognosis of ovarian cancer, for follow-up of ovarian tumor metastasis and for monitoring the efficacy of therapy in patients with ovarian carcinomas.

Original languageEnglish (US)
Pages (from-to)1973-1979
Number of pages7
JournalAnticancer Research
Volume24
Issue number3 B
StatePublished - May 2004
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Vascular Endothelial Growth Factor A
Neoplasm Metastasis
Survival
Serum
Neoplasms
Therapeutics
Carcinoma
Ascites
Tumor Biomarkers
Blood Donors
Biomarkers
Enzyme-Linked Immunosorbent Assay
Sensitivity and Specificity

Keywords

  • Ovarian cancer
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Li, L., Wang, L., Zhang, W., Tang, B., Zhang, J., Song, H., ... Li, Q. Q. (2004). Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Research, 24(3 B), 1973-1979.

Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. / Li, Li; Wang, Limei; Zhang, Wei; Tang, Bujian; Zhang, Jieqing; Song, Honglin; Yao, Desheng; Tang, Yong; Chen, Xinqiu; Yang, Zhihua; Wang, Gangduo; Li, Xiping; Zhao, Jinshun; Ding, Hong; Reed, Eddie; Li, Qingdi Q.

In: Anticancer Research, Vol. 24, No. 3 B, 05.2004, p. 1973-1979.

Research output: Contribution to journalArticle

Li, L, Wang, L, Zhang, W, Tang, B, Zhang, J, Song, H, Yao, D, Tang, Y, Chen, X, Yang, Z, Wang, G, Li, X, Zhao, J, Ding, H, Reed, E & Li, QQ 2004, 'Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer', Anticancer Research, vol. 24, no. 3 B, pp. 1973-1979.
Li, Li ; Wang, Limei ; Zhang, Wei ; Tang, Bujian ; Zhang, Jieqing ; Song, Honglin ; Yao, Desheng ; Tang, Yong ; Chen, Xinqiu ; Yang, Zhihua ; Wang, Gangduo ; Li, Xiping ; Zhao, Jinshun ; Ding, Hong ; Reed, Eddie ; Li, Qingdi Q. / Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. In: Anticancer Research. 2004 ; Vol. 24, No. 3 B. pp. 1973-1979.
@article{b70e244240dd4963b59bce97f608192c,
title = "Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer",
abstract = "Vascular endothelial growth factor (VEGF) has been shown to play an important role in tumor growth and progression. However, the clinical implications of VEGF expression in ovarian tumors are not fully understood. We therefore investigated the serum level of VEGF in patients with ovarian tumors and explored the potential use of VEGF as a tumor marker for diagnosis, treatment and prognosis of human ovarian cancer. The serum VEGF (sVEGF) levels in 120 patients with ovarian carcinoma, 25 patients with benign ovarian tumor and 90 healthy female blood donors were measured by an enzyme-linked immunosorbent assay in this study. We also determined the levels of sVEGF in patients with epithelial ovarian cancer before and after surgery. Our results showed that: (i) ovarian cancer patients had significantly higher levels of sVEGF compared to those of patients with benign ovarian tumor or those of healthy individuals. As a cut-off at 100 pg/ml, the sensitivity and specificity of sVEGF levels for diagnosing ovarian carcinoma were 77.1{\%} and 87{\%}, respectively. (ii) sVEGF levels were markedly elevated in patients with advanced stage or poorly-differentiated ovarian cancer, as well as in those with more ascites (>500 ml), as compared to patients with early stage and well-differentiated ovarian cancer, or those with less ascites (<500 ml). However, there was no significant difference in sVEGF levels among different pathological subtypes of ovarian carcinoma. (iii) The postoperative sVEGF levels were significantly lower than the preoperative sVEGF levels. (iv) We measured significantly higher levels of sVEGF in patients with metastasis as compared to patients lacking metastasis. Lastly, (v) the average survival-time in patients with higher levels of sVEGF (>100 pg/ml) was 28 months, while the average survival-time in patients with lower levels of sVEGF (<100 pg/ml) was 35 months, indicating that the elevations in sVEGF level are correlated with patient survival and tumor metastasis in ovarian carcinoma. These data suggest that VEGF may be a useful serological biomarker for clinical diagnosis and prognosis of ovarian cancer, for follow-up of ovarian tumor metastasis and for monitoring the efficacy of therapy in patients with ovarian carcinomas.",
keywords = "Ovarian cancer, VEGF",
author = "Li Li and Limei Wang and Wei Zhang and Bujian Tang and Jieqing Zhang and Honglin Song and Desheng Yao and Yong Tang and Xinqiu Chen and Zhihua Yang and Gangduo Wang and Xiping Li and Jinshun Zhao and Hong Ding and Eddie Reed and Li, {Qingdi Q.}",
year = "2004",
month = "5",
language = "English (US)",
volume = "24",
pages = "1973--1979",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 B",

}

TY - JOUR

T1 - Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer

AU - Li, Li

AU - Wang, Limei

AU - Zhang, Wei

AU - Tang, Bujian

AU - Zhang, Jieqing

AU - Song, Honglin

AU - Yao, Desheng

AU - Tang, Yong

AU - Chen, Xinqiu

AU - Yang, Zhihua

AU - Wang, Gangduo

AU - Li, Xiping

AU - Zhao, Jinshun

AU - Ding, Hong

AU - Reed, Eddie

AU - Li, Qingdi Q.

PY - 2004/5

Y1 - 2004/5

N2 - Vascular endothelial growth factor (VEGF) has been shown to play an important role in tumor growth and progression. However, the clinical implications of VEGF expression in ovarian tumors are not fully understood. We therefore investigated the serum level of VEGF in patients with ovarian tumors and explored the potential use of VEGF as a tumor marker for diagnosis, treatment and prognosis of human ovarian cancer. The serum VEGF (sVEGF) levels in 120 patients with ovarian carcinoma, 25 patients with benign ovarian tumor and 90 healthy female blood donors were measured by an enzyme-linked immunosorbent assay in this study. We also determined the levels of sVEGF in patients with epithelial ovarian cancer before and after surgery. Our results showed that: (i) ovarian cancer patients had significantly higher levels of sVEGF compared to those of patients with benign ovarian tumor or those of healthy individuals. As a cut-off at 100 pg/ml, the sensitivity and specificity of sVEGF levels for diagnosing ovarian carcinoma were 77.1% and 87%, respectively. (ii) sVEGF levels were markedly elevated in patients with advanced stage or poorly-differentiated ovarian cancer, as well as in those with more ascites (>500 ml), as compared to patients with early stage and well-differentiated ovarian cancer, or those with less ascites (<500 ml). However, there was no significant difference in sVEGF levels among different pathological subtypes of ovarian carcinoma. (iii) The postoperative sVEGF levels were significantly lower than the preoperative sVEGF levels. (iv) We measured significantly higher levels of sVEGF in patients with metastasis as compared to patients lacking metastasis. Lastly, (v) the average survival-time in patients with higher levels of sVEGF (>100 pg/ml) was 28 months, while the average survival-time in patients with lower levels of sVEGF (<100 pg/ml) was 35 months, indicating that the elevations in sVEGF level are correlated with patient survival and tumor metastasis in ovarian carcinoma. These data suggest that VEGF may be a useful serological biomarker for clinical diagnosis and prognosis of ovarian cancer, for follow-up of ovarian tumor metastasis and for monitoring the efficacy of therapy in patients with ovarian carcinomas.

AB - Vascular endothelial growth factor (VEGF) has been shown to play an important role in tumor growth and progression. However, the clinical implications of VEGF expression in ovarian tumors are not fully understood. We therefore investigated the serum level of VEGF in patients with ovarian tumors and explored the potential use of VEGF as a tumor marker for diagnosis, treatment and prognosis of human ovarian cancer. The serum VEGF (sVEGF) levels in 120 patients with ovarian carcinoma, 25 patients with benign ovarian tumor and 90 healthy female blood donors were measured by an enzyme-linked immunosorbent assay in this study. We also determined the levels of sVEGF in patients with epithelial ovarian cancer before and after surgery. Our results showed that: (i) ovarian cancer patients had significantly higher levels of sVEGF compared to those of patients with benign ovarian tumor or those of healthy individuals. As a cut-off at 100 pg/ml, the sensitivity and specificity of sVEGF levels for diagnosing ovarian carcinoma were 77.1% and 87%, respectively. (ii) sVEGF levels were markedly elevated in patients with advanced stage or poorly-differentiated ovarian cancer, as well as in those with more ascites (>500 ml), as compared to patients with early stage and well-differentiated ovarian cancer, or those with less ascites (<500 ml). However, there was no significant difference in sVEGF levels among different pathological subtypes of ovarian carcinoma. (iii) The postoperative sVEGF levels were significantly lower than the preoperative sVEGF levels. (iv) We measured significantly higher levels of sVEGF in patients with metastasis as compared to patients lacking metastasis. Lastly, (v) the average survival-time in patients with higher levels of sVEGF (>100 pg/ml) was 28 months, while the average survival-time in patients with lower levels of sVEGF (<100 pg/ml) was 35 months, indicating that the elevations in sVEGF level are correlated with patient survival and tumor metastasis in ovarian carcinoma. These data suggest that VEGF may be a useful serological biomarker for clinical diagnosis and prognosis of ovarian cancer, for follow-up of ovarian tumor metastasis and for monitoring the efficacy of therapy in patients with ovarian carcinomas.

KW - Ovarian cancer

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=3242658330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242658330&partnerID=8YFLogxK

M3 - Article

C2 - 15274387

AN - SCOPUS:3242658330

VL - 24

SP - 1973

EP - 1979

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 B

ER -